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Context: Limited screening suggests that three germline mutations
in the aryl hydrocarbon receptor interacting protein (AIP) gene are not
involved in sporadic pituitary tumorigenesis. Multiple novel muta-
tions of this gene have since been identified in familial isolated pi-
tuitary adenoma cohorts.
Objective: The objective of the study was to undertake full AIP
coding sequence screening to assess for the presence of germline and
somatic mutations in European Union subjects with sporadic pitu-
itary tumors.
Design: The study design was the analysis of DNA from peripheral
blood lymphocytes and analysis of exons 1–6 and paraexonic intron
sequences of AIP. Multiplex ligation-dependent probe amplification
was used to screen separate sporadic pituitary tumor tissue samples
for discrete and extensive deletions or mutations of the AIP gene.
Setting: The study was conducted in university tertiary referral
Clinical Genetics, Molecular Biology, and Endocrinology
Departments.
Results: In 107 patients [prolactinomas (n 49), nonfunctioning tu-
mors (n  29), somatotropinomas (n  26), ACTH-secreting tumors
(n 2), TSH-secreting tumors (n 1)], no germline mutations of AIP
were demonstrated. Among a group of 41 tumor samples from other
subjects, a novel AIP mutation (R22X) was found in one sample in
which the corresponding allele was deleted; follow-up screening of the
patient demonstrated a germline R22X AIP mutation.
Conclusions: AIPmutations do not appear to play a prominent role
in sporadic pituitary tumorigenesis in this population of European
subjects. (J Clin Endocrinol Metab 92: 1952–1955, 2007)
MOLECULAR GENETIC STUDY of pituitary tumorshas identified a variety of mutations or abnormal
expression pattern that may play a role in tumorigenesis.
Well-recognized examples include mutations in the Gs
gene,PTTG overexpression, anddecreasedMEG3 expression
(1–4). MEN1 and PRKAR1A gene mutations play a critical
role in endocrine tumorigenesis in multiple endocrine neo-
plasia-1 (MEN1) and Carney complex (CNC) (5, 6) but are of
limited significance in sporadic pituitary tumors (7, 8). Thus,
interest remains high in the identification of new molecular
mechanisms to explain sporadic adenoma formation (9).
Aryl hydrocarbon receptor interacting protein (AIP), a
330-amino-acid protein present in the pituitary, interacts
with the aryl hydrocarbon receptor and heat shock protein
90 dimer; AIP is involved in mediating cellular responses to
environmental toxins like dioxin (10, 11). Mutations that
remove conserved tetratricopeptide repeat domains at the
carboxy terminal of AIP abrogate proper interaction with its
receptor and heat shock protein 90, thereby disrupting nu-
clear localization (11). Vierimaa et al. (12) first reported the
involvement of threeAIPmutations in pituitary adenomas in
non-MEN1, non-CNC families from Finland and Italy.
Among the Finnish cohort, twoAIPmutations were noted in
germline and somatic DNA from sporadic pituitary ade-
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noma patients (12). Recently Daly et al. (13, 14) described the
clinical and genetic features of families exhibiting familial
isolated pituitary adenomas (FIPAs). Among 73 FIPA fam-
ilies, 10 AIPmutations were present among 11 families; nine
of these mutations were novel (13). Yu et al. (15) demon-
strated that the three germline mutations described by Vi-
erimaa et al. were not prevalent among U.S. patients with
sporadic pituitary adenomas. We undertook a study of 107
subjects with sporadic pituitary adenomas and 41 separate
sporadic pituitary tumor samples to screen for germline and
somatic mutations in the full coding sequence of AIP.
Subjects and Methods
Subjects
The study was performed in 107 patients with sporadic pituitary
adenomas from university hospital centers in France (Marseilles), Bel-
gium (Lie`ge), and Italy (L’Aquila). There were 49 subjects with pro-
lactinomas [17 males, 32 females; mean (sd) age at diagnosis: 33.9 
13.0 yr; 70.2%macroadenomas, 52.5% cavernous sinus invasion], 26with
somatotropinomas [17males, nine females,mean (sd) age at diagnosis:
44.4 13.3 yr; 86.4%macroadenomas, 45.0% cavernous sinus invasion],
29 with nonfunctioning pituitary adenomas [NFPAs; 15 males, 14 fe-
males; mean (sd) age at diagnosis: 50.6  13.1 yr; 100% macroadeno-
mas, 58.8% cavernous sinus invasion], two females with noninvasive
ACTH-secreting microadenomas [mean (sd) age at diagnosis: 32.5 
4.9 yr], and one male subject with a noninvasive TSH-secreting mi-
croadenoma diagnosed at age 48 yr.
None of the subjects had a history of MEN1, CNC, or FIPA. Twelve
subjects (11.2%) had other endocrine tumors: parathyroid adenoma (n
10), pancreatic endocrine tumor (n  1), and thymoma (n  1); MEN1
gene mutations were outruled by gene sequencing. All subjects gave
their written informed consent to participate in the study, which was
approved by the local ethics committee.
Pituitary tumor samples
Forty-one frozen tissue samples from patients with sporadic pituitary
tumors (different from the patients above) were collected as previously
described (16) and studied for AIP gene mutations. These tumors, clas-
sified by immunohistochemical staining for pituitary hormones, in-
cluded 23 somatotropinomas [13 males, 10 females; mean (sd) age at
diagnosis: 42  13.9 yr] and 18 gonadotropinomas [nine males, nine
females; mean (sd) age at diagnosis: 45  13.7 yr] and were clear of
residual normal pituitary tissue before genetic analysis. Gs sequence
was performed in all somatotropinoma samples, as describedpreviously
(16); seven tumors had point mutations in Gs, indicating the presence
of the gsp oncogene.
Genomic analysis of AIP and MEN1
Using DNA isolated from peripheral blood, exons of the AIP and
MEN1 genes were amplified using exon flanking primers (12, 17). Apart
from exons 4 and 5 of AIP, the same primers were used for gene se-
quencing using aCEQ8000 sequencer (BeckmanCoulter, Fullerton, CA).
The primers for AIP exons 4 and 5 were: GACGCAGCTGTGGTGTCC
(AIP4F) and CTGAGGGGGAGGATGGAT (AIP5F). The primers used
for sequencing AIP exons 1, 2, 3, and 6 and theMEN1 gene are available
on request.
AIP single-nucleotide polymorphism patterns were studied using a
reference population of 86 normal individuals from Belgium (n  31),
France (n  25), and Italy (n  30). In addition, an international panel
of reference populations were analyzed as follows: exons 2 and 5 [Ap-
plera Genomics Initiative (AGI) Caucasian and African American sam-
ples, Coriell Cell Repositories], exon 4 (CEU;Utah residents of northern/
western European ancestry), and exon 6 [Centre d’Etude du
Polymorphisme Humain (CEPH)].
Multiplex ligation-dependent probe amplification (MLPA)
analysis
Loss of heterozygosity (LOH) within the AIP gene and along larger
segments of chromosome 11q was assessed in tumor samples using
MLPA.MLPA probe design has been described previously (18). Control
probe-pairs that were specific to unrelated genes on chromosomes 7 and
17 were also designed. All probes had amplification products from 87
to 136 bp in length and had an annealing temperature higher than 70 C
as per the RAW Probe program (MRC-Holland, Amsterdam, The
Netherlands). PCR products were analyzed on an ABI3100 capillary
electrophoresis apparatus (Applied Biosystems, Lennik, Belgium). Copy
number quantification involved normalization of the peak area of the
AIP-specific MLPA probe by dividing it by the combined areas of the
control probes. This ratio was compared with the similar ratio obtained
from control DNA. LOH was observed when the wild-type signal was
reduced by 35–60% for each AIP-specific probe.
Results
AIP analysis in genomic DNA
Analysis of the coding sequence of AIP in genomic DNA
from 107 subjects with sporadic pituitary adenomas revealed
no mutations. The genotype frequencies of polymorphisms
were similar to those of the reference populations (Table 1).
AIP analysis in pituitary tumor DNA
MLPA analysis revealed deletions at the AIP locus in two
of 41 frozen pituitary tumor fragments [somatotropinoma
(n  2)]. In one somatotropinoma, a nonsense mutation
p.Arg22X (CGATGA) at exon 1 of AIP was found, indi-
cating a hemizygotic state with the loss of wild-type allele
(GenBank accession no. EF158450). This male subject pre-
sented with acromegaly at a young age (24 yr) due to a
macroadenoma that secreted high levels of GH and was
resistant to somatostatin agonist therapy. Radiotherapy was
required 1 yr postoperatively due to activity of the residual
tumor. Analysis of peripheral blood DNA in the patient also
revealed a germline p.Arg22Xmutation. Therewas no family
history of pituitary adenomas in this case. The other soma-
totropinoma sample with a large deletion that included the
AIP andMEN1 loci came from a youngmalewith an invasive
tumor. However, the corresponding AIP or MEN1 genes
were intact in the other allele.
The genotype frequencies of all AIP polymorphisms were
similar to those of the reference populations (Table 1).
Discussion
The involvement of AIP mutations in pituitary tumori-
genesis was first suggested by Vierimaa et al. (12), who de-
scribed three mutations (Q14X, R304X, and IVS3–1GA) in
subjects with somatotropinomas and prolactinomas. Daly et
al. (13) recently described a further nine AIP mutations
(R16H, G47_R54del, Q142X, E174 frameshift, Q217X, Q239X,
K241E, R271W, and Q285 frameshift) in a cohort of 73 fam-
ilies with FIPA. Among these 12 described mutations, the
majority lead to early stop codons and protein truncation,
which would remove the third tetratricopeptide repeat do-
main and the last five carboxy-terminal amino acids that are
necessary for the biological activity of AIP (10). Q14X and
IVS3–1GA occurred in Finnish individuals with sporadic
pituitary tumors; LOH at the AIP locus was shown in all
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tumor samples analyzed. Subsequently Yu et al. (15) ana-
lyzed genomic DNA from 66 individuals with sporadic pi-
tuitary adenomas treated in a single tertiary referral center
in the United States; they looked exclusively for the three
mutations described previously by Vierimaa et al. (16). Be-
cause none of the patients had any of these three AIP mu-
tations, the authors concluded that AIP was unlikely to be
involved in the pathogenesis of sporadic pituitary tumors in
a predominantly Californian group.
The results of the current study confirm the findings of Yu
et al. (15) and expand our understanding of this issue in a
number of ways. We undertook sequencing of the entire
coding sequence of AIP. In that way we can conclude with
certainty that AIP mutations did not play an important role
in the pathogenesis of sporadic pituitary adenomas in our
cohort. In the U.S. cohort, three of the 66 individuals (4.5%)
had a family history of pituitary adenomas (two subjectswith
prolactinomas and one with a NFPA). These patients, neg-
ative forMEN1,may have comprised FIPA families. In FIPA,
AIPmutations occur in about 15% of families, and tumors in
such families can include somatotropinomas, mixed GH/
prolactin-secreting tumors, prolactinomas, and NFPA (13).
The majority of FIPA families, including 50% of those with
familial somatotropinomas, are, however, negative for AIP
mutations, indicating that other unidentified pathogenic fac-
tors may be involved. We also chose to screen DNA from
subjects from three separate countries (France, Belgium, and
Italy); absence of AIP mutations in genomic DNA from this
geographically dispersed group supports the contention that
founder effects may be involved in the frequent occurrence
of the Q14X mutation in the Finnish cohort (12, 15).
Mutations in AIP are not, however, altogether absent
among patients with sporadic pituitary adenomas. Our
screening of tumor tissue revealed a p.Arg22X mutation in
oneAIP allele and a deletion of the other allele. Subsequently
a germline AIP was also demonstrated in the same patient.
The clinical characteristics (young age, large/aggressive tu-
mor) of the patient are similar to those of other patients with
AIP mutations recently described (13). This patient had no
family history of pituitary adenomas or other endocrine dis-
ease. A tumor sample from another patient with a soma-
totropinoma had a deletion that also included both AIP and
MEN1, but both genes in the other allele were wild type. This
raises the possibility that a mutation in another gene in this
region of 11q13 could be involved in pituitary tumorigenesis
in such patients.
This study confirms that germline mutations of AIP are
infrequently found in patients with sporadic pituitary ade-
nomas in continental Europe. Founder effects should be con-
sidered when extrapolating from AIP mutation prevalence
among genetically delimited populations. Given that at least
13 AIP mutations have been described in association with
pituitary adenomas, fullAIP sequencing is needed to outrule
AIP involvement in sporadic pituitary tumorigenesis among
other populations worldwide.
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TABLE 1. Frequencies of AIP gene polymorphisms in subjects with sporadic pituitary adenomas
Exon Sequence variation Genotype
Controls (n  86) Genomic (n  107) Somatic (n  41)
Frequency Count Frequency Count Frequency Count
2 p.Asp44Asp (rs11822907) c.132CT C/C 1 86 1 107 1 41
C/T 0 0 0 0 0 0
T/T 0 0 0 0 0 0
4 p.Asp172Asp (rs2276020) c.516CT C/C 0.98 84 0.97 104 0.98 40
C/T 0.02 2 0.03 3 0.02 1
T/T 0 0 0 0 0 0
5 p.Gln228Lys (rs641081) c.682CA C/C 0 0 0.01 1 0 0
C/A 0 0 0.04 4 0 0
A/A 1 86 0.95 102 1 41
6 p.Ile327Ile (rs1049565) c.981CT C/C 1 86 1 107 1 41
C/T 0 0 0 0 0 0
T/T 0 0 0 0 0 0
The control population comprised normal subjects from Belgium (n  31), France (n  25), and Italy (n  30), and the polymorphism
frequencies were similar to those seen in the genomic and somatic populations. An additional 92 control samples from international sources
were also studied (data not shown). These includedAGI for single-nucleotide polymorphisms located in exons 2 and 5, CEU for exon 4, andCEPH
in exon 6. The populations included: AGI (Caucasian and African-American samples from Coriell Cell Repositories Collection); CEU CEPH
(Utah residents with ancestry from northern and western Europe); CEPH the genomic DNA was comprised of U.S. (Utah; 93%), French (4%),
and Venezuelan (3%) samples from Coriell Cell Repository, which were pooled in equimolar amounts for use. Polymorphism frequencies were
similar to those seen in the Belgian-French-Italian control population and the genomic and somatic DNA samples from patients with sporadic
pituitary adenomas.
1954 J Clin Endocrinol Metab, May 2007, 92(5):1952–1955 Barlier et al. • AIP Mutations in Sporadic Pituitary Adenomas
 by Albert Beckers on May 9, 2007 jcem.endojournals.orgDownloaded from 
References
1. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D,
Dufour H, Enjalbert A, Jaquet P 1998 Prognostic and therapeutic conse-
quences of Gsmutations in somatotroph adenomas. J Clin Endocrinol Metab
83:1604–1610
2. Landis CA,Masters SB, SpadaA, PaceAM, BourneHR,Vallar L 1989GTPase
inhibiting mutations activate the  chain of Gs and stimulate adenylyl cyclase
in human pituitary tumors. Nature 340:692–696
3. Pei L, Melmed S 1997 Isolation and characterization of a pituitary tumor-
transforming gene (PTTG). Mol Endocrinol 11:433–441
4. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A 2005 Hypermethylation of
the promoter region is associated with the loss of MEG3 gene expression in
human pituitary tumors. J Clin Endocrinol Metab 90:2179–2186
5. Zhuang Z, Ezzat SZ, Vortmeyer AO, Weil R, Oldfield EH, Park WS, Pack S,
Huang S, Agarwal SK, Guru SC, Manickam P, Debelenko LV, Kester MB,
Olufemi SE, Heppner C, Crabtree JS, Burns AL, Spiegel AM, Marx SJ,
Chandrasekharappa SC, Collins FS, Emmert-Buck MR, Liotta LA, Asa SL,
Lubensky IA 1997Mutations of theMEN1 tumor suppressor gene in pituitary
tumors. Cancer Res 57:5446–5451
6. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA 2000
Genetic heterogeneity and spectrum of mutations of the PPKAR1A gene in
patients with the Carney complex. Hum Mol Genet 9:3037–3046
7. Poncin J, Stevenaert A, Beckers A 1999 Somatic MEN1 gene mutation does
not contribute significantly to sporadic pituitary tumorigenesis. Eur J Endo-
crinol 140:573–576
8. Kaltsas GA, Kola B, Borboli N, Morris DG, Gueorguiev M, Swords FM,
Czirjak S, Kirschner LS, Stratakis CA, Korbonits M, Grossman AB 2002
Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other
pituitary tumors. Clin Endocrinol (Oxf) 57:443–448
9. Marx SJ, Simonds WF 2005 Hereditary hormone excess: genes, molecular
pathways, and syndromes. Endocr Rev 26:615–661
10. Petrulis JR, Perdew GH 2002 The role of chaperone proteins in the aryl
hydrocarbon receptor core complex. Chem Biol Interact 141:25–40
11. Harper PA, Riddick DS, Okey AB 2006 Regulating the regulator: factors that
control levels and activity of the aryl hydrocarbon receptor. Biochem Phar-
macol 72:267–279
12. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A,
TuppurainenK, Ebeling TM, Salmela PI, PaschkeR,Gundogdu S,DeMenis
E, MakinenMJ, Launonen V, Karhu A, Aaltonen LA 2006 Pituitary adenoma
predisposition caused by germline mutations in the AIP gene. Science 312:
1228–1230
13. Daly AF, Vanbellinghen J-F, Khoo SK, Jaffrain-Rea M-L, Naves LA, Guitel-
manMA,Murat A, Emy P, Gimenez-Roqueplo A-P, Tamburrano G, Raverot
G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P,
Gatta B, ChabreO, Sabate´MI, Bertagna X,Garcia BasavilbasoN, Stalldecker
G, Colao A, Ferolla P, We´meau J-L, Caron P, Sadoul J-L, Oneto A, Archam-
beaud F, Calender A, Sinilnikova O, Fajardo Montan˜ana C, Cavagnini F,
Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V,
Brue T, Bours V, Teh BT, Beckers A 2007 Aryl hydrocarbon receptor-
interacting protein gene mutations in familial isolated pituitary adenomas:
analysis in 73 families. J Clin Endocrinol Metab 92:1891–1896
14. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tam-
burrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy
P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J,
Wemeau JL, DeHerderW,Archambeaud F, Stevenaert A, Calender A,Murat
A, Cavagnini F, Beckers A 2006 Clinical characterization of familial isolated
pituitary adenomas. J Clin Endocrinol Metab 91:3316–3323
15. Yu R, Bonert V, Saporta I, Raffel LJ, Melmed S 2006 AIP variants in sporadic
pituitary adenomas. J Clin Endocrinol Metab 91:5126–5129
16. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P, Enjalbert A
1999 Impact of gsp oncogene on the expression of genes coding for Gs, Pit-1,
Gi2, and somatostatin receptor 2 in human somatotroph adenomas: involve-
ment in octreotide sensitivity. J Clin Endocrinol Metab 84:2759–2765
17. Reynaud R, Barlier A, Vallette-Kasic S, Saveanu A, Guillet MP, Simonin G,
Enjalbert A, Valensi P, Brue T 2005 An uncommon phenotype with familial
central hypogonadism caused by a novel PROP1 gene mutant truncated in the
transactivation domain. J Clin Endocrinol Metab 90:4880–4887
18. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G
2002 Relative quantification of 40 nucleic acid sequences bymultiplex ligation-
dependent probe amplification. Nucleic Acids Res 30:e57
JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the
endocrine community.
Barlier et al. • AIP Mutations in Sporadic Pituitary Adenomas J Clin Endocrinol Metab, May 2007, 92(5):1952–1955 1955
 by Albert Beckers on May 9, 2007 jcem.endojournals.orgDownloaded from 
